Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy.
Bottom Line: Results of the univariate analysis have been reported previously.The a priori-planned multiple linear regression analysis, which accounted for the effects of disease progression and several other possibly confounding variables on quality of life, showed a significant advantage for epoetin alfa over placebo for the five scales (all, P<0.05), and confirmed the results of the univariate analysis.These findings provide evidence that increasing haemoglobin levels by epoetin alfa administration can significantly improve cancer patients' quality of life.
Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. firstname.lastname@example.orgShow MeSH
Related in: MedlinePlus
Mentions: QoL mean change scores by treatment group: results of univariate (Littlewood et al, 2001) and multiple linear regression analyses* (FACT-G Total scale and FACT-Fatigue Subscale). *P values adjusted for multiple comparisons (sequentially rejective Bonferroni procedure).
Affiliation: Cancer Research UK Psychosocial Oncology Group, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9QG, UK. email@example.com